MHRA reissues LABA advice

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a reminder to prescribers on the use of long-acting ß2 agonists.

LABAs are indicated for long-term use and not to relieve acute asthma symptoms.
LABAs are indicated for long-term use and not to relieve acute asthma symptoms.

The advice is consistent with the guidelines issued by the British Thoracic Society and Scottish Intercollegiate Guidelines Network. It reminds prescribers:

  • To prescribe long-acting β2 agonists (LABAs) only with inhaled corticosteroids (ICS) and when ICS alone fail to control asthma symptoms.
  • Not to initiate LABA treatment in patients with rapidly deteriorating asthma.
  • To use the lowest effective dose, review treatment regularly, and discontinue if there is no benefit.
  • To consider stepping-down when good long-term asthma control is achieved.
  • Not to prescribe LABA for exercise-induced asthma without regular ICS (a short-acting β2-agonist should be used instead).
  • To prescribe combination inhalers when appropriate.

See the MIMS summary of BTS/SIGN asthma guidelines for more information.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Third tiotropium inhaler adds to treatment options for COPD patients

Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New shingles vaccine awaits decision on NHS use

New shingles vaccine awaits decision on NHS use

Shingrix, which is now available privately in the UK,...

Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...